VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
LearnAll lessons
Candlestick Patterns44 candles, each on two real charts
Pattern GuidesThe playbooks' setups on real breakouts
GlossaryInvesting terms in plain English
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
VRDN
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
VRDNViridian Therapeutics, Inc.
$30.06$2.7B
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
HomeStocksVRDNFinancials

Viridian Therapeutics, Inc. (VRDN) Income Statement

14Y historyFree accessUpdated daily

Revenue remains highly erratic, moving from near-zero levels around $72K through most of 2024 and early 2025 to $70.6M in 2025Q3 and $25.8M in 2026Q3, while operating margin stayed deeply negative at -4.0% to -1,303.7% across the period, showing that milestone timing rather than product demand drives reported results.

Income StatementBalance SheetCash FlowRatios

VRDN Income Statement

Annual statement

VRDN Income Statement

Viridian Therapeutics, Inc. (VRDN) annual income statement — 14-year revenue, gross profit & net income history

AnnualQuarterly
MetricTTMDec'25Dec'24Dec'23Dec'22Dec'21Dec'20Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12
Sales/Revenue26.31M70.85M302K314K1.77M2.96M1.05M4.46M8.39M4M3.34M2.54M4.32M4.32M4.41M
Revenue Growth %-62.83%23359.93%-3.82%-82.28%-40.2%182.19%-76.46%-46.8%109.49%19.96%31.48%-41.25%0.08%-2.03%-
Cost of Goods Sold1.85M0000028.3M030.42M19.62M2.55M2.47M3.24M2.5M3.04M
COGS % of Revenue------2695.62%-362.76%490.21%76.36%97.4%75.07%57.89%69.05%
Gross Profit24.46M70.85M302K314K1.77M2.96M-27.25M4.46M-22.04M-15.62M789K66K1.08M1.82M1.36M
Gross Margin %92.98%100%100%100%100%100%-2595.62%100%-262.76%-390.21%23.64%2.6%24.93%42.11%30.95%
Gross Profit Growth %-23359.93%-3.82%-82.28%-40.2%110.87%-710.94%120.25%-41.07%-2079.72%1095.45%-93.87%-40.74%33.26%-
Operating Expenses493.13M434.24M299.34M254.76M136.08M82.69M83.13M46.44M41.47M30.54M10.46M11.25M8.04M2.26M4.46M
OpEx % of Revenue-612.91%99118.21%81135.03%7679.23%2790.79%7916.76%1041.02%494.51%762.8%313.55%443.38%186.2%52.44%101.19%
Selling, General & Admin184.94M95.31M61.08M95M35.18M25.8M13.27M11.65M11.05M10.91M9.57M10.25M7.75M2.17M4.23M
SG&A % of Revenue-134.53%20226.16%30254.46%1985.44%870.91%1263.33%261.06%131.76%272.6%286.93%403.9%179.42%50.2%96.08%
Research & Development308.51M338.93M238.25M159.76M100.89M56.89M28.3M34.79M30.42M19.62M888K1M293K96.85K225.38K
R&D % of Revenue-478.38%78892.05%50880.57%5693.79%1919.88%2695.62%779.96%362.76%490.21%26.61%39.48%6.78%2.24%5.12%
Other Operating Expenses-320K0000041.56M00000000
Operating Income-468.66M-363.39M-299.04M-254.45M-134.3M-79.73M-110.38M-41.98M-33.08M-26.53M-12.51M-11.19M-6.87M-196.21K-4.03M
Operating Margin %-1781.38%-512.91%-99018.21%-81035.03%-7579.23%-2690.79%-10512.38%-941.02%-394.51%-662.8%-374.83%-440.78%-158.96%-4.55%-91.4%
Operating Income Growth %--21.52%-17.52%-89.46%-68.45%27.77%-162.94%-26.89%-24.69%-112.12%-11.81%-62.91%-3399.77%95.13%-
EBITDA-467.96M-362.94M-298.5M-253.93M-134.05M-79.61M-110.14M-41.69M-32.8M-26.22M-12.17M-11M-6.72M-47.9K-3.88M
EBITDA Margin %-1778.71%-512.27%-98839.4%-80868.79%-7564.84%-2686.74%-10489.62%-934.57%-391.16%-655.11%-364.61%-433.53%-155.63%-1.11%-88.12%
EBITDA Growth %-42.82%-21.59%-17.55%-89.43%-68.39%27.72%-164.18%-27.1%-25.09%-115.53%-10.58%-63.66%-13936.08%98.77%-
D&A (Non-Cash Add-back)701K460K540K522K255K120K239K288K281K308K341K184K144K148.31K144.29K
EBIT-435.47M-337.65M-266.9M-235.89M-129.39M-79.41M-40.52M-41.04M-31.83M-26.13M-12.58M-11.19M-6.87M-197K-4.03M
Net Interest Income6.04M22.45M29.09M16.72M4.43M315K-335K106K381K20K-95K-141K-1.02M-1.96M-1.59M
Interest Income33.69M27.4M32.13M18.56M4.92M318K173K941K1.25M403K00000
Interest Expense27.65M4.95M3.05M1.85M486K3K508K835K873K383K95K141K1.02M1.96M1.59M
Other Income/Expense15.08M20.79M29.09M16.72M4.43M315K-335K106K381K20K-166K-141K-1.02M-1.71M-1.59M
Pretax Income-453.58M-342.6M-269.95M-237.73M-129.87M-79.41M-110.72M-41.87M-32.7M-26.51M-12.67M-11.33M-7.89M-2.16M-5.62M
Pretax Margin %-1724.06%-483.56%-89387.09%-75711.46%-7329.23%-2680.16%-10544.29%-938.65%-389.97%-662.3%-379.8%-446.34%-182.64%-50.03%-127.51%
Income Tax00000000095K95K001.96M0
Effective Tax Rate %0%0%0%0%0%0%0%0%0%-0.36%-0.75%0%0%-90.91%0%
Net Income-453.58M-342.6M-269.95M-237.73M-129.87M-79.41M-110.72M-41.87M-32.7M-26.51M-12.67M-11.33M-7.89M-2.16M-7.21M
Net Margin %-1724.06%-483.56%-89387.09%-75711.46%-7329.23%-2680.16%-10544.29%-938.65%-389.97%-662.3%-379.8%-446.34%-182.64%-50.03%-163.67%
Net Income Growth %-50.21%-26.91%-13.55%-83.05%-63.54%28.27%-164.41%-28.04%-23.35%-109.18%-11.88%-43.57%-265.33%70.05%-
Net Income (Continuing)-453.58M-342.6M-269.95M-237.73M-129.87M-79.41M-110.72M-41.87M-32.7M-26.51M-12.67M-11.33M-7.89M-2.16M-5.62M
Discontinued Operations000000000000000
Minority Interest000000000000000
EPS (Diluted)-4.00-3.32-3.98-5.31-3.91-6.66-31.20-20.31-16.57-20.66-17.57-21.00-52.46-11.48-38.75
EPS Growth %-19.08%16.58%25.05%-35.81%41.29%78.65%-53.62%-22.57%19.8%-17.59%16.33%59.97%-356.97%70.37%-
EPS (Basic)--3.32-3.98-5.31-3.91-6.66-31.20-20.31-16.57-20.66-17.57-21.00-52.46-11.48-38.75
Diluted Shares Outstanding113.41M84.8M67.89M44.76M32.09M11.92M3.56M2.09M1.97M1.28M721.41K539.46K150.39K188.12K186.09K
Basic Shares Outstanding113.41M84.8M67.89M44.76M32.09M11.92M3.56M2.09M1.97M1.28M721.41K539.45K150.39K188.12K186.09K
Dividend Payout Ratio---------------

Key Metrics

Growth RegimeMixed
ProfitabilityWeak
Balance SheetAdequate
Cash FlowBurning
Top Statement Risk

Cash runway vs Phase 3 funding

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q3)

Lumpy Revenue Masks Persistent Burn Trend

According to reported quarterly figures, VRDN revenue swung from $70.6M in 2025Q3 to $25.8M in 2026Q3 after sitting near $72K for most of 2024 and early 2025, a pattern driven by milestone timing rather than product demand.

The sequence of near-zero quarters followed by single large receipts suggests revenue reflects licensing and milestone events instead of a recurring commercial base. Because the operating loss persisted through the revenue spikes, investors should treat headline growth rates as distorted by a small denominator. The durability of this top line remains unestablished until product-level sales can be separated from one-time receipts.

Gross Margin Reflects Milestone Accounting

Based on reported figures, VRDN's gross margin printed at 94.1% in 2026Q3 and 100% in several quarters, yet operating margin stood at -4.0% and -444.6% in the same window, showing gross margin carries little analytical weight here.

Gross margin is high because milestone revenue carries negligible cost of goods, not because the company has demonstrated pricing power. Without a manufacturing and distribution cost base, the metric cannot be benchmarked against commercial peers such as Red Violet's 83.7%. Investors should look past gross margin to the operating line until product COGS become observable.

Operating Loss Scales With R&D Spend

As reported in financial statements, VRDN's R&D expense rose from $56.2M in 2024Q2 to $89.2M in 2025Q4 while operating losses widened from $72.2M to $122.7M, indicating negative operating leverage.

Operating loss has grown in step with R&D rather than with revenue, which is the expected pattern for a company funding late-stage trials. SG&A also climbed from $14.4M to $57.6M over the period, implying commercial-launch preparation costs are now entering the cost base. Operating leverage will not turn positive until revenue becomes recurring and scalable relative to this fixed spend.

Stock Compensation Dominates Loss Quality

Based on EDBL's reported figures, the question for VRDN is how much of its net loss reflects cash burn versus non-cash charges, with stock-based compensation reaching $30.4M in 2026Q2 against a net loss of $127.1M.

Stock-based compensation has risen substantially over the period, which lowers the cash-burn portion of the reported loss but adds dilution cost to shareholders. Reported EPS of -0.81 to -1.23 per quarter is not meaningful for valuation until the revenue base stabilizes. Investors should assess net loss alongside SBC and share count growth rather than in isolation.

Burn Rate Threatens Trial Funding Path

Based on reported figures, VRDN's operating losses of roughly $100M to $125M in recent quarters, against a stated cash position near $212M, suggest limited headroom for Phase 3 completion without further capital raises.

If quarterly burn persists near recent levels, the cash balance could be consumed within a few quarters, raising the probability of dilutive equity financing. Lumvoa's early launch commentary may help, but the absence of disclosed EPS and guidance limits confidence that commercial revenue will offset the spend. This warrants close monitoring of the next filing for runway guidance.

VRDN — Frequently Asked Questions

Quick answers to the most common questions about buying VRDN stock.

What was Viridian Therapeutics, Inc.'s (VRDN) revenue in 2025?

For fiscal year 2025, Viridian Therapeutics, Inc. (VRDN) reported total revenue of $70.8M. This represents a 1508.0% increase compared to $4.4M in 2012.

Is Viridian Therapeutics, Inc. (VRDN) profitable?

Viridian Therapeutics, Inc. (VRDN) reported a net loss of $342.6M for the fiscal year ending 2025.

What is Viridian Therapeutics, Inc.'s operating profit margin?

Viridian Therapeutics, Inc. (VRDN) reported an operating income of $-363.4M, resulting in an operating profit margin of -512.9%. This margin reflects the operational efficiency of the business before interest and taxes.

What is Viridian Therapeutics, Inc.'s gross profit and gross margin?

Viridian Therapeutics, Inc. (VRDN) generated $70.8M in gross profit for the year, representing a gross profit margin of 100.0%. This demonstrates the company's core pricing power and production efficiency.